Compare Adaptive Biotechnologies Corp (ADPT) vs American Financial Group Inc (AFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs American Financial Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while American Financial Group Inc trades at $145.06 (market cap $11.97B). The key difference: American Financial Group Inc is far larger — about 3× Adaptive Biotechnologies Corp's market cap, and American Financial Group Inc pays a 2.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AFG | |
|---|---|---|
Market Cap | $4.04B | $11.97B |
Sector | Health | Financials |
52-Week High | $25.45 | $148.71 |
52-Week Low | $12.30 | $124.18 |
Enterprise Value | $4.10B | $12.35B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
American Financial Group (AFG) trades at $144.82, up 0.66% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 is projected at $8.2 billion with an 11.66% margin. Analysts have a consensus price target of $160.67, with 41% recommending buy.
AFG presents a positive outlook with solid earnings beats and a shareholder-friendly dividend policy, but faces risks from competitive pressures and potential market volatility. The stock's current valuation at a P/E of 12.62 offers room for growth relative to historical averages, supported by institutional interest and consistent cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →
